Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine
- 31 December 2003
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 13 (6) , 401-407
- https://doi.org/10.1016/j.semcancer.2003.09.003
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Immunoregulatory T cells in cancer immunotherapyExpert Opinion on Biological Therapy, 2002
- Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human BloodThe Journal of Experimental Medicine, 2001
- Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancerCancer, 2000
- Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma?Annals of Surgical Oncology, 2000
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993Journal of Clinical Oncology, 1999
- Where have all the T cells gone? Mechanisms of immune evasion by tumorsImmunology Today, 1999
- Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+T lymphocytesProceedings of the National Academy of Sciences, 1999
- Induction of antigen-specific T cell anergy: An early event in the course of tumor progressionProceedings of the National Academy of Sciences, 1998
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-ACellular Immunology, 1992